Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Resveratrol in Primary Knee Osteoarthritis
NCT02905799Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing Oral resveratrol with Oral Placebo (2 arms). Primary endpoint: Mean change from baseline in knee pain in the previous 48 hours at 6 months. Started Nov 2017; status: completed.
02
Drugs
resveratrol
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02905799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905799.